Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Third-party inspection talks

This article was originally published in The Gray Sheet

Executive Summary

NEMA expects to meet with FDA within the next two weeks to continue discussions on "flexible" approaches to the MDUFMA-mandated program, such as multiple-stage inspections conducted within a two-year period and bundled appraisals. National Electrical Manufacturers Association reps met with FDA Assistant Commissioner for Regulatory Affairs Steve Niedelman in July to confer about possible solutions, following the trade group's May 23 comments on the agency's program guidance (1"The Gray Sheet" June 2, 2003, p. 18). FDA received 23 applications for accreditation status by the Aug. 25 deadline (2"The Gray Sheet" Sept. 1, 2003, p. 14)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018989

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel